The viral hepatitis B care cascade: A population-based comparison of immigrant groups.
Cohort Studies
Continuity of Patient Care
/ organization & administration
Emigrants and Immigrants
/ statistics & numerical data
Epidemiological Monitoring
Female
Health Services Needs and Demand
Hepatitis B
/ diagnosis
Hepatitis B Surface Antigens
/ isolation & purification
Hepatitis B e Antigens
/ isolation & purification
Humans
Male
Mass Screening
/ methods
Medication Therapy Management
/ statistics & numerical data
Middle Aged
Ontario
/ epidemiology
Prevalence
Retrospective Studies
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
28
06
2021
received:
08
03
2021
accepted:
09
08
2021
pubmed:
20
9
2021
medline:
4
3
2022
entrez:
19
9
2021
Statut:
ppublish
Résumé
The global burden of viral hepatitis B is substantial, and monitoring infections across the care cascade is important for elimination efforts. There is little information on care disparities by immigration status, and we aimed to quantify disease burden among immigrant subgroups. In this population-based, retrospective cohort study, we used linked laboratory and health administrative records to describe the HBV care cascade in five distinct stages: (1) lifetime prevalence; (2) diagnosis; (3) engagement with care; (4) treatment initiation; and (5) treatment continuation. Infections were identified based on at least one reactive antigen or nucleic acid test, and lifetime prevalence was estimated as the sum of diagnosed and estimated undiagnosed cases. Care cascades were compared between long-term residents and immigrant groups, including subgroups born in hepatitis B endemic countries. Stratified analyses and multivariable Poisson regression were used to identify drivers for cascade progression. Between January 1997 and December 2014, 2,014,470 persons were included, 50,475 with infections, of whom 30,118 were engaged with care, 11,450 initiated treatment, and 6554 continued treatment >1 year. Lifetime prevalence was estimated as 163,309 (1.34%) overall, 115,722 (3.42%) among all immigrants, and 50,876 (9.37%) among those from highly endemic countries. Compared to long-term residents, immigrants were more likely to be diagnosed (adjusted rate ratio [aRR], 4.55; 95% CI, 4.46, 4.63), engaged with care (aRR, 1.07; 95% CI, 1.04, 1.09), and initiate treatment (aRR, 1.09; 95% CI, 1.03, 1.16). In conclusion, immigrants fared well compared to long-term residents along the care cascade, having higher rates of diagnosis and slightly better measures in subsequent cascade stages, although intensified screening efforts and better strategies to facilitate linkage to care are still needed.
Sections du résumé
BACKGROUND AND AIMS
The global burden of viral hepatitis B is substantial, and monitoring infections across the care cascade is important for elimination efforts. There is little information on care disparities by immigration status, and we aimed to quantify disease burden among immigrant subgroups.
APPROACH AND RESULTS
In this population-based, retrospective cohort study, we used linked laboratory and health administrative records to describe the HBV care cascade in five distinct stages: (1) lifetime prevalence; (2) diagnosis; (3) engagement with care; (4) treatment initiation; and (5) treatment continuation. Infections were identified based on at least one reactive antigen or nucleic acid test, and lifetime prevalence was estimated as the sum of diagnosed and estimated undiagnosed cases. Care cascades were compared between long-term residents and immigrant groups, including subgroups born in hepatitis B endemic countries. Stratified analyses and multivariable Poisson regression were used to identify drivers for cascade progression. Between January 1997 and December 2014, 2,014,470 persons were included, 50,475 with infections, of whom 30,118 were engaged with care, 11,450 initiated treatment, and 6554 continued treatment >1 year. Lifetime prevalence was estimated as 163,309 (1.34%) overall, 115,722 (3.42%) among all immigrants, and 50,876 (9.37%) among those from highly endemic countries. Compared to long-term residents, immigrants were more likely to be diagnosed (adjusted rate ratio [aRR], 4.55; 95% CI, 4.46, 4.63), engaged with care (aRR, 1.07; 95% CI, 1.04, 1.09), and initiate treatment (aRR, 1.09; 95% CI, 1.03, 1.16).
CONCLUSIONS
In conclusion, immigrants fared well compared to long-term residents along the care cascade, having higher rates of diagnosis and slightly better measures in subsequent cascade stages, although intensified screening efforts and better strategies to facilitate linkage to care are still needed.
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-689Subventions
Organisme : CIHR
ID : NHC-142832
Pays : Canada
Organisme : CIHR
ID : MOP-103553
Pays : Canada
Informations de copyright
© 2021 American Association for the Study of Liver Diseases.
Références
Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(Suppl 3):S158-68.
Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1-21, vii.
Thio CL, Guo N, Xie C, Nelson KE, Ehrhardt S. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis. 2015;15:981-5.
Lok ASF, McMahon BJ, Brown RS, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284-306.
Vineberg R. Healthy enough to get in: the evolution of Canadian immigration policy related to immigrant health. J Int Migr Integr. 2015;16:279-97.
Sharma S, Carballo M, Feld JJ, Janssen HLA. Immigration and viral hepatitis. J Hepatol. 2015;63:515-22.
Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C, et al. An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States. Hepatology. 2021;74:607-26.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-55.
Pampalon R, Hamel D, Gamache P, Philibert MD, Raymond G, Simpson A. An area-based material and social deprivation index for public health in Quebec and Canada. Can J Public Health. 2012;103(Suppl 2):S17-22.
Yasseen A III, Kwong J, Kustra R, Holder L, Chung H, MacDonald L, et al. Validating viral hepatitis B and C diagnosis codes: a retrospective analysis using Ontario’s health administrative data. Can J Public Health. 2021;112:502-12.
Szklo M, Nieto J. Epidemiology beyond the basics, 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2014.
Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6.
Lapointe-Shaw L, Chung H, Holder L, Kwong JC, Sander B, Austin PC, et al. Diagnosis of chronic hepatitis B pericomplication: risk factors and trends over time. Hepatology. 2021;73:2141-54.
Reitmanova S, Gustafson DL, Ahmed R. “Immigrants can be deadly”: critical discourse analysis of racialization of immigrant health in the Canadian press and public health policies. Can J Commun. 2015;40:471-87.
Public Health Agency of Canada. Report on hepatitis B and C in Canada: 2017; 2019 [cited 2021 Feb 27]. Available from: https://www.canada.ca/en/services/health/publications/diseases-conditions/report-hepatitis-b-c-canada-2017.html
Coppola N, Alessio L, Pisaturo M, Macera M, Sagnelli C, Zampino R, et al. Hepatitis B virus infection in immigrant populations 2015 advances in hepatitis B virus. World J Hepatol. 2015;7:2955-61.
Coffin C, Fung S, Alvarez F, Cooper C, Doucette K, Fournier C, et al. Management of hepatitis B virus infection: 2018 guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. Can Liver J. 2018;1:156-217.
Wong WWL, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int. 2011;31:1179-90.
Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC Public Health. 2015;15:151.
Wong KM, Lee JJ, Wong A, Liu G, Sherman M, Cleary SP, et al. Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians. J Clin Oncol. 2014;32(Suppl 3):289.
Liou IW, Nguyen MH. The cascade of care in chronic hepatitis B. Curr Hepatol Rep. 2016;15:209-19.
Vang ZM, Sigouin J, Flenon A, Gagnon A. Are immigrants healthier than native-born Canadians? A systematic review of the healthy immigrant effect in Canada. Ethn Health. 2017;22:209-41.
Salas-Wright CP, Vaughn MG, Clark TT, Terzis LD, Cόrdova D. Substance use disorders among first- and second- generation immigrant adults in the United States: evidence of an immigrant paradox? J Stud Alcohol Drugs. 2014;75:958-67.
Fong E. Immigration and its impacts on Canadian cities. In: Prato GB, editor. Beyond multiculturalism, 1st ed. London: Routledge; 2016:51-68.
Wang L, Hu W. Immigrant health, place effect and regional disparities in Canada. Soc Sci Med. 2013;98:8-17.
Younossi ZM, Stepanova M, Younossi I, Pan CQ, Janssen HLA, Papatheodoridis G, et al. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. Clin Gastroenterol Hepatol. 2019;17:1641-2.e1.
Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol. 2013;11:565-71.
Uribe LA, Nguyen N, Kim L, Trinh HN, Wong C, Wong C, et al. Rates of treatment eligibility in follow-up of patients with chronic hepatitis B (CHB) across various clinical settings who were initially ineligible at presentation. Dig Dis Sci. 2016;61:618-25.
Liou IW, Nguyen MH. The cascade of care in chronic hepatitis B. Curr Hepatol Rep. 2016;15:209-19.
Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat. 2011;18:377-83.
Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z, et al. Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun. 2018;2:1160-7.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322:349-54.
Tagkou NM, Kondylis G, Cholongitas E. Pregnancy and viral hepatitis: current concepts. Curr Pharm Des. 2020 Dec 9. https://doi.org/10.2174/1381612826666201210113841. [Epub ahead of print]
Biondi MJ, Marchand-Austin A, Cronin K, Nanwa N, Ravirajan V, Mandel E, et al. Health services: prenatal hepatitis b screening, and hepatitis B burden among children, in Ontario: a descriptive study. CMAJ. 2020;192:E1299-305.
History of hepatitis B vaccine; 2021. [cited 2021 May 8]. Available from: https://www.hepb.org/prevention-and-diagnosis/vaccination/history-of-hepatitis-b-vaccine/
Statistics Canada. 150 years of immigration in Canada. Canadian MEGATRENDS; 2016 [cited 25 Jun 2021]. Available from: https://www150.statcan.gc.ca/n1/pub/11-630-x/11-630-x2016006-eng.htm
Government of Canada. Message from the Minister of Health-world hepatitis day; 2016 [cited 2021 Feb 27]. Available from: https://www.canada.ca/en/health-canada/